Scott Bizily Biography and Net Worth

Scott P. Bizily, JD, PhD, has served as 4DMT’s Chief Legal Officer since September 2021. Dr. Bizily previously served as General Counsel at Synthego Corporation, a privately-held, venture-backed life sciences tools and services company specializing in genome engineering, from January 2019 to September 2021 and as Director, Corporate Counsel at BioMarin Pharmaceutical Inc., a publicly-held biopharmaceutical company specializing in rare diseases, from 2010 to 2019. From 2005 to 2007, Dr. Bizily practiced in patent litigation at Weil, Gotshal & Manges LLP, and from 2007 to 2009 in life sciences licensing and corporate partnering at Cooley Godward Kronish LLP. Dr. Bizily was a postdoctoral fellow at University of Pennsylvania from 2001 to 2002. He received his BA in Ecology and Evolutionary Biology from Princeton University in 1994, his PhD in Genetics from the University of Georgia in 2001, and his JD from the University of Pennsylvania Carey Law School in 2005.

What is Scott Bizily's net worth?: The estimated net worth of Scott Bizily is at least $90.91 thousand as of June 23rd, 2026. Bizily owns 8,617 shares of 4D Molecular Therapeutics stock worth more than $90,909 as of August 6th. This net worth estimate does not reflect any other investments that Bizily may own. Learn More about Scott Bizily's net worth.
How do I contact Scott Bizily?: The corporate mailing address for Bizily and other 4D Molecular Therapeutics executives is , , . 4D Molecular Therapeutics can also be reached via phone at 510-505-2680 and via email at [email protected]. Learn More on Scott Bizily's contact information.
Has Scott Bizily been buying or selling shares of 4D Molecular Therapeutics?: Scott Bizily has not been actively trading shares of 4D Molecular Therapeutics during the last ninety days. Most recently, Scott Bizily sold 9,810 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a transaction totalling $117,720.00. Following the completion of the sale, the insider now directly owns 8,617 shares of the company's stock, valued at $103,404. Learn More on Scott Bizily's trading history.
Who are 4D Molecular Therapeutics' active insiders?: 4D Molecular Therapeutics' insider roster includes Scott Bizily (Insider), Ashoo Gupta (VP), David Kirn (CEO), and David Schaffer (Director). Learn More on 4D Molecular Therapeutics' active insiders.
Are insiders buying or selling shares of 4D Molecular Therapeutics?: During the last twelve months, insiders at the sold shares 14 times. They sold a total of 210,403 shares worth more than $2,334,647.04. The most recent insider tranaction occured on August, 3rd when insider David Kirn sold 12,415 shares worth more than $124,770.75. Insiders at 4D Molecular Therapeutics own 7.9% of the company. Learn More about insider trades at 4D Molecular Therapeutics.
Information on this page was last updated on 8/3/2026.

Scott Bizily Insider Trading History at 4D Molecular Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/23/2026	Sell	9,810	$12.00	$117,720.00	8,617
12/16/2025	Sell	1,635	$10.90	$17,821.50	3,594
11/17/2025	Sell	1,635	$10.59	$17,314.65	3,594
10/24/2025	Sell	2,678	$12.00	$32,136.00	3,594
10/16/2025	Sell	1,635	$10.17	$16,627.95	5,188
10/9/2025	Sell	2,408	$10.00	$24,080.00	5,188
9/23/2025	Sell	2,407	$8.00	$19,256.00	7,596
9/16/2024	Sell	500	$16.33	$8,165.00	6,781
7/16/2024	Sell	1,750	$27.11	$47,442.50	6,781
7/11/2024	Sell	1,996	$25.00	$49,900.00	6,781
7/1/2024	Sell	4,248	$21.36	$90,737.28	1,737
5/16/2024	Sell	1,750	$25.45	$44,537.50	1,737
4/16/2024	Sell	1,750	$25.74	$45,045.00	1,737
4/1/2024	Sell	8,153	$31.78	$259,102.34	1,737
3/27/2024	Sell	5,833	$35.04	$204,388.32	1,737
3/18/2024	Sell	1,750	$31.27	$54,722.50	1,737
2/27/2024	Sell	1,909	$30.00	$57,270.00	1,737
2/16/2024	Sell	1,750	$27.67	$48,422.50	1,737
2/8/2024	Sell	6,244	$27.50	$171,710.00	1,737
6/8/2023	Sell	3,750	$20.85	$78,187.50	1,737
6/1/2023	Sell	2,247	$18.31	$41,142.57	1,737
4/21/2023	Sell	3,750	$20.00	$75,000.00	2,109
3/1/2023	Sell	2,248	$19.30	$43,386.40	2,109
12/1/2022	Sell	6,000	$22.79	$136,740.00	2,482

Scott Bizily Buying and Selling Activity at 4D Molecular Therapeutics

4D Molecular Therapeutics Company Overview

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Today's Range

Now: $10.55

$10.21

$10.69

50 Day Range

MA: $10.70

$8.64

$13.30

2 Week Range

Now: $10.55

$5.33

$14.00

Volume

295,016 shs

Average Volume

644,498 shs

Market Capitalization

$551.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.73